Welcome to our dedicated page for Onconetix SEC filings (Ticker: ONCO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, FDA correspondence, and licensing details can make Onconetix’s SEC documents some of the most technical in biotechnology. Finding ENTADFI revenue trends inside a 300-page 10-K or tracking when executives file Form 4s right after pivotal prostate-cancer milestones shouldn’t slow your research.
Stock Titan’s AI reads every Onconetix annual report 10-K simplified, Onconetix quarterly earnings report 10-Q filing, and Onconetix 8-K material events explained the moment they hit EDGAR. Our platform converts medical jargon and risk disclosures into plain language, flags key numbers, and delivers real-time alerts for Onconetix Form 4 insider transactions real-time. If you have ever typed “understanding Onconetix SEC documents with AI” or “Onconetix insider trading Form 4 transactions,” this page answers those questions in one place.
Use the filings to:
- Compare R&D spend on prostate cancer diagnostics across quarters
- Monitor Onconetix executive stock transactions Form 4 before regulatory catalysts
- Review licensing revenue disclosures and acquisition terms
- Examine board pay in the latest Onconetix proxy statement executive compensation
- Dive into trial outcome narratives with AI-powered highlights
Each document comes with a concise summary, critical-metric dashboard, and cross-linked definitions so Onconetix earnings report filing analysis becomes a five-minute task instead of a late-night marathon. With comprehensive coverage, expert context, and automated updates, Onconetix SEC filings explained simply means you can focus on decisions, not document hunting.
Onconetix, Inc. filed an S-1 to register up to 5,100,000 shares of common stock for resale by Keystone Capital Partners under an equity line of credit (ELOC). The company is not selling shares in this prospectus and will not receive proceeds from the Selling Stockholder’s resales. Separately, Onconetix may sell shares to Keystone under the ELOC and may receive up to
Through
Onconetix, Inc. filed a Form D for a Regulation D private offering reporting a
The offering included multiple security types — equity, debt, and options/warrants — and accepted investments from 11 investors with a stated minimum investment of
Onconetix, Inc. filed a Form 8-K reporting several material corporate actions disclosed in press releases dated September 26, 2025. The filing references a PIPE Financing and Settlement Agreement and a separate press release announcing the Termination of Merger Agreement. It also lists transaction exhibits including a Certificate of Designations that authorizes Series D Preferred Stock, a Form of Warrant, and the PIPE Financing and Settlement Agreement as exhibits. The filing describes an Alternate Conversion Right that permits holders to convert Preferred Shares into Common Stock after certain triggering events and after the Stockholder Approval Date at specified alternate conversion prices. The document is signed by the company’s Interim Chief Executive Officer and Interim Chief Financial Officer.
Onconetix, Inc. filed a Form 8-K reporting a material event: the filing includes a License Agreement dated
This filing discloses the existence and filing of the license agreement and press release but does not include the license terms, financial consideration, milestones, or other commercial details. Investors should note the counterparties and dates disclosed; the filing itself provides notice of the agreement rather than substantive commercial or financial metrics.
Onconetix, Inc. reported a series of waiver agreements with Veru, Inc. extending payment dates for promissory notes multiple times during 2025. The company and Veru executed waivers on March 31, April 23, June 30, July 31 and August 28, 2025, each extending the due dates for the April Veru Note and related Veru Notes, with the most recent extension moving the April Veru Note to September 19, 2025.
The filing also attaches new promissory notes dated August 28, 2025 with Keystone Capital Partners, LLC and KCP Fund I, LLC, plus a Second Amended and Restated Promissory Note and an August 28, 2025 waiver between Veru and the company as exhibits. The disclosures reference earlier forbearance and note documents filed in 2023 and 2024 for full terms.
Andrew Oakley, a non-employee director of Onconetix, Inc. (ONCO), reported changes to his restricted stock awards. A restricted stock award originally granted March 23, 2025 was modified on August 15, 2025 to change the vesting date from August 31, 2025 to August 31, 2026, contingent on continued service as a non-employee director. The filing shows an additional restricted stock award of 618 shares granted that vests August 31, 2026 under the issuer's 2022 Equity Incentive Plan. The amounts are presented on a post 1-for-85 reverse split basis effected June 13, 2025, and total beneficial ownership following the transactions is 638 shares.
Tarsh Simon, a non-employee director of Onconetix, Inc. (ONCO), reported changes to his restricted stock awards. An original restricted stock award granted September 26, 2024 was modified on August 15, 2025 to extend its vesting date from August 31, 2025 to August 31, 2026, conditional on continued service as a non-employee director. The issuer completed a 1-for-85 reverse stock split on June 13, 2025; all share amounts in this report are presented on a post-split basis. The reporting person was also granted a separate restricted stock award of 618 shares that will vest in full on August 31, 2026 if he continues to serve as a non-employee director. The Form 4 is signed by Simon Tarsh on August 19, 2025.
Thomas Meier, a director of Onconetix, Inc. (ticker: ONCO), reported changes to his restricted stock holdings on Form 4 dated 08/15/2025. The filing shows a modification of a previously granted restricted stock award (originally granted 09/26/2024) that changes the vesting date from August 31, 2025 to August 31, 2026, conditioned on continued service as a non-employee director through that date. The filing also reports a restricted stock award of 618 shares that will vest in full on August 31, 2026, and a reported amount of 39 shares related to the modified award, with 657 shares shown as beneficially owned following the transactions (amounts presented on a post 1-for-85 reverse split basis).
The filing discloses the issuer effected a 1-for-85 reverse split on June 13, 2025 and states all share amounts are post-split. No cash consideration is reported for the awards.
Onconetix, Inc. (ONCO) Form 4 filing reports changes to director Timothy Ramdeen's restricted stock awards. The filing shows the Original Award granted 9/26/2024 had its vesting date changed on 08/15/2025 from vesting in full on 08/31/2025 to vesting in full on 08/31/2026, contingent on continued service as a non-employee director. The issuer effected a 1-for-85 reverse stock split on 06/13/2025 and all amounts are shown post-split. The filing also reports a separate restricted stock award of 618 shares that will vest in full on 08/31/2026, subject to continued service. Reported transactions on 08/15/2025 include acquisitions and a disposition, with 658 shares shown as beneficially owned following the transactions.
FAQ
What is the current stock price of Onconetix (ONCO)?
What is the market cap of Onconetix (ONCO)?
